Baird Maintains Outperform on ORIC Pharmaceuticals, Raises Price Target to $27
Portfolio Pulse from Benzinga Newsdesk
Baird analyst Michael Ulz maintains an Outperform rating on ORIC Pharmaceuticals and raises the price target from $15 to $27.
August 16, 2023 | 12:05 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Baird analyst Michael Ulz maintains an Outperform rating on ORIC Pharmaceuticals and raises the price target from $15 to $27.
The news of Baird analyst maintaining an Outperform rating on ORIC Pharmaceuticals and raising the price target from $15 to $27 is directly related to ORIC. This is likely to have a positive impact on the stock price in the short term as it indicates the analyst's positive outlook on the company.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100